Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bispecific antibody drug conjugates: Making 1+1>2
Yilin Gu, Zhijia Wang, Yuxi Wang
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 5, pp. 1965-1986
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

A pivotal decade for bispecific antibodies?
Marlena Surowka, Christian Klein
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 19
Natural-source payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions
Cuiping Li, Kourong Shi, Siyuan Zhao, et al.
Pharmacological Research (2024) Vol. 207, pp. 107341-107341
Open Access | Times Cited: 5
Resistance to antibody–drug conjugates: A review
Sijia Li, Xinyu Zhao, Kai Fu, et al.
Acta Pharmaceutica Sinica B (2025) Vol. 15, Iss. 2, pp. 737-756
Open Access
Key considerations based on pharmacokinetic/pharmacodynamic in the design of antibody-drug conjugates
Yangyang Gao, Yuwei Xia, Yixin Chen, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
A Strategy for Simultaneous Engineering of Interspecies Cross-Reactivity, Thermostability, and Expression of a Bispecific 5T4 x CD3 DART® Molecule for Treatment of Solid Tumors
Renhua Huang, Michael Spliedt, Tom Kaufman, et al.
Antibodies (2025) Vol. 14, Iss. 1, pp. 7-7
Open Access
Diverse Roles of Antibodies in Antibody–Drug Conjugates
Aiko Yamaguchi, H. Charles Manning
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 180-180
Open Access
Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies
Yuying Jiang, Yuance Xu, Junqi He, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
A novel anti-HER2/EGFR bispecific antibody–drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs
Huixia Huang, Yuxin Zhou, Chengzhang Shang, et al.
Investigational New Drugs (2025)
Closed Access
Development of a bispecific antibody–drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors
Meiying Luo, Xiaohuan Wang, Guohua Yu, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
Evolving Landscape of HER2-Targeted Therapies for Gastric Cancer Patients
Lijuan He, Ben Liu, Zhuanfang Wang, et al.
Current Treatment Options in Oncology (2025)
Closed Access
Bispecific antibodies (bsAbs) directed against PD-1/PD-L1 and CTLA-4; a mini review
Amirhossein Mardi, Leili Aghebati‐Maleki
Human Antibodies (2025)
Closed Access
Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances
Lorenzo Guidi, Julian Etessami, Carmine Valenza, et al.
American Society of Clinical Oncology Educational Book (2025) Vol. 45, Iss. 3
Closed Access
Enhanced Targeted Drug Delivery System to Control Avidity and Drug Encapsulation Using E2 Nanocages and SpyTag/SpyCatcher
Do-Hee Ahn, Sun Hee Park, Sangha Lee, et al.
ACS Biomaterials Science & Engineering (2025)
Closed Access
Single-Domain Antibodies as Antibody–Drug Conjugates: From Promise to Practice—A Systematic Review
Víctor Manuel Medina Pérez, Marta Baselga, Alberto J. Schuhmacher
Cancers (2024) Vol. 16, Iss. 15, pp. 2681-2681
Open Access | Times Cited: 4
The Evolution of Antibody‐Drug Conjugates: Toward Accurate DAR and Multi‐specificity
Wenge Dong, Wanqi Wang, Chan Cao
ChemMedChem (2024) Vol. 19, Iss. 17
Closed Access | Times Cited: 3
The Evolving Paradigm of Antibody–Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases
Peyton C. High, Cara Guernsey-Biddle, Shraddha Subramanian, et al.
Pharmaceutics (2024) Vol. 16, Iss. 7, pp. 890-890
Open Access | Times Cited: 3
Unlocking the potential of bispecific ADCs for targeted cancer therapy
Hongye Zeng, Wenjing Ning, Xue Liu, et al.
Frontiers of Medicine (2024) Vol. 18, Iss. 4, pp. 597-621
Closed Access | Times Cited: 3
Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges
A. Raja, Abhishek Kasana, Vaishali Verma
Molecular Biotechnology (2024)
Closed Access | Times Cited: 3
Therapeutic potential of cis-targeting bispecific antibodies
Rob Oslund, Pamela M. Holland, Scott A. Lesley, et al.
Cell chemical biology (2024) Vol. 31, Iss. 8, pp. 1473-1489
Closed Access | Times Cited: 2
Antibody–drug conjugates: prospects for the next generation
Meriem Grairi, Marc Le Borgne
Drug Discovery Today (2024) Vol. 29, Iss. 12, pp. 104241-104241
Open Access | Times Cited: 2
Comprehensive review of bispecific antibody constructs in multiple myeloma: affinities, dosing strategies and future perspectives
Johannes M. Waldschmidt, Leo Rasche, K. Martin Kortüm, et al.
Clinical Lymphoma Myeloma & Leukemia (2024)
Closed Access | Times Cited: 1
Efficacy and safety of antibody–drug conjugates in the treatment of urothelial cell carcinoma: a systematic review and meta-analysis of prospective clinical trials
Junwei Ren, Zeyu Chen, Yunjin Bai, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Antibody-drug conjugates for hepato-pancreato-biliary malignancies: “Magic bullets” to the rescue?
Charalampos Theocharopoulos, Ioannis A. Ziogas, Charalampos-Christos Douligeris, et al.
Cancer Treatment Reviews (2024) Vol. 129, pp. 102806-102806
Closed Access | Times Cited: 1
Prospects and Current Challenges of Extracellular Vesicle-Based Biomarkers in Cancer
S R Lawrence, Karan M. Shah
Biology (2024) Vol. 13, Iss. 9, pp. 694-694
Open Access | Times Cited: 1
Targeted Therapy in Breast Cancer: Advantages and Advancements of Antibody–Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs
Abhik Mukherjee, Debasish Bandyopadhyay
Cancers (2024) Vol. 16, Iss. 20, pp. 3517-3517
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top